MEDP - メッドペ―ス・ホ―ルディングス (Medpace Holdings Inc.) メッドペ―ス・ホ―ルディングス

 MEDPのチャート


 MEDPの企業情報

symbol MEDP
会社名 Medpace Holdings Inc (メッドペ―ス・ホ―ルディングス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   IT・通信(IT_Communications)
概要 事業概要 メッドペース・ホールディングス(Medpace Holdings Inc.)は臨床契約研究機関である。同社は臨床研究に基づく医薬品及び医療機器開発サービスを提供する。同社は医薬品、バイオ技術、および医療機器企業と協力して、臨床試験の開発・実施を行う。同社の麻薬開発サービスは、フルサービス第I-IV臨床開発サービスを主として、開発計画の設計、コーディネートされた中央検査室、プロジェクト管理、規制業務、臨床モニタリング、データ管理および分析、薬物動態検査の新薬申請の提出、および販売後のマーケティング臨床サポートを含む。また、バイオアナリティカルラボサービス、臨床ヒト薬理学、イメージングサービス、および臨床試験のための心電図読み取りのサポートを提供する。同社の事業は、主に北米、欧州、アジアに拠点を置く。   メッドペ―ス・ホ―ルディングスは米国の臨床試験受託企業。持株会社体制で、子会社を通じ臨床試験サ―ビスをバイオ医薬品企業や医療器具メ―カ―などの医療業界全体に提供する。主に心臓病、代謝性疾患、がん、内分泌系疾患、神経系疾患などに対する臨床試験をフェ―ズ1からフェ―ズ4まで実施する。本社はオハイオ州シンシナティ。   Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH.
本社所在地 5375 Medpace Way Cincinnati OH 45227 USA
代表者氏名 August J. Troendle 8月J.Troendle
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 513-579-9911
設立年月日 41671
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 2500人
url www.medpace.com
nasdaq_url https://www.nasdaq.com/symbol/medp
adr_tso
EBITDA EBITDA(百万ドル) 118.75300
終値(lastsale) 57
時価総額(marketcap) 2027575728
時価総額 時価総額(百万ドル) 1865.725
売上高 売上高(百万ドル) 556.54600
企業価値(EV) 企業価値(EV)(百万ドル) 232.587
当期純利益 当期純利益(百万ドル) 49.25000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Medpace Holdings Inc revenues increased 57% to $333.2M. Net income applicable to common stockholders increased 72% to $31M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Amortization decrease of 22% to $14.8M (expense) Miscellaneous (expense) income net increase from $497K (expense) to $325K (income).

 MEDPのテクニカル分析


 MEDPのニュース

   The Future of the Bioanalytical Testing Services Industry (2020-2025) Featuring Charles River, Medpace, Wuxi Apptec, Eurofins Scientific, IQVIA, SGS, and More - ResearchAndMarkets.com  2020/06/03 08:55:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Bioanalytical Testing Services Market by Type, Application, End User - Global Forecasts to 2025 " report has been added to ResearchAndMarkets.com's offering. The global bioanalytical testing services market is projected to reach USD 3.72 billion by 2025 from an estimated USD 2.13 billion in 2020, at a CAGR of 11.8% during the forecast period. This report analyzes the bioanalytical testing services market and aims at estimating the market size and future growth pote
   Medpace (MEDP) Q1 Earnings Miss Estimates  2020/04/28 23:05:05 Zacks Investment Research
Medpace (MEDP) delivered earnings and revenue surprises of -1.30% and 1.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Medpace : Q1 2020 Earnings Presentation | MarketScreener  2020/04/28 20:38:10 MarketScreener
Q1 2020 FINANCIAL RESULTS APRIL 28, 2020 F O RWA R D L O O K I N G S TAT E M E N T S & … | April 28, 2020
   Medpace Holdings, Inc. Reports First Quarter 2020 Results  2020/04/28 20:15:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2020. First Quarter 2020 Financial Results Revenue for the three months ended March 31, 2020 increased 15.0% to $230.9 million, compared to $200.7 million for the comparable prior-year period. On a constant currency organic basis, revenue for the first quarter of 2020 increased 15.2% compared to the first quarter of 2019. Backlog as of March 31,
   Medpace Holdings, Inc. to Report First Quarter 2020 Financial Results on April 28, 2020  2020/04/03 20:05:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq:MEDP) (“Medpace”) today announced that it will report its first quarter 2020 financial results after the market close on Tuesday, April 28, 2020. The Company will host a conference call the following morning, Wednesday, April 29, 2020, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 5203559. To access the conference call via
   The Future of the Bioanalytical Testing Services Industry (2020-2025) Featuring Charles River, Medpace, Wuxi Apptec, Eurofins Scientific, IQVIA, SGS, and More - ResearchAndMarkets.com  2020/06/03 08:55:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Bioanalytical Testing Services Market by Type, Application, End User - Global Forecasts to 2025 " report has been added to ResearchAndMarkets.com's offering. The global bioanalytical testing services market is projected to reach USD 3.72 billion by 2025 from an estimated USD 2.13 billion in 2020, at a CAGR of 11.8% during the forecast period. This report analyzes the bioanalytical testing services market and aims at estimating the market size and future growth pote
   Medpace (MEDP) Q1 Earnings Miss Estimates  2020/04/28 23:05:05 Zacks Investment Research
Medpace (MEDP) delivered earnings and revenue surprises of -1.30% and 1.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Medpace : Q1 2020 Earnings Presentation | MarketScreener  2020/04/28 20:38:10 MarketScreener
Q1 2020 FINANCIAL RESULTS APRIL 28, 2020 F O RWA R D L O O K I N G S TAT E M E N T S & … | April 28, 2020
   Medpace Holdings, Inc. Reports First Quarter 2020 Results  2020/04/28 20:15:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2020. First Quarter 2020 Financial Results Revenue for the three months ended March 31, 2020 increased 15.0% to $230.9 million, compared to $200.7 million for the comparable prior-year period. On a constant currency organic basis, revenue for the first quarter of 2020 increased 15.2% compared to the first quarter of 2019. Backlog as of March 31,
   Medpace Holdings, Inc. to Report First Quarter 2020 Financial Results on April 28, 2020  2020/04/03 20:05:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq:MEDP) (“Medpace”) today announced that it will report its first quarter 2020 financial results after the market close on Tuesday, April 28, 2020. The Company will host a conference call the following morning, Wednesday, April 29, 2020, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 5203559. To access the conference call via
   The Future of the Bioanalytical Testing Services Industry (2020-2025) Featuring Charles River, Medpace, Wuxi Apptec, Eurofins Scientific, IQVIA, SGS, and More - ResearchAndMarkets.com  2020/06/03 08:55:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Bioanalytical Testing Services Market by Type, Application, End User - Global Forecasts to 2025 " report has been added to ResearchAndMarkets.com's offering. The global bioanalytical testing services market is projected to reach USD 3.72 billion by 2025 from an estimated USD 2.13 billion in 2020, at a CAGR of 11.8% during the forecast period. This report analyzes the bioanalytical testing services market and aims at estimating the market size and future growth pote
   Medpace (MEDP) Q1 Earnings Miss Estimates  2020/04/28 23:05:05 Zacks Investment Research
Medpace (MEDP) delivered earnings and revenue surprises of -1.30% and 1.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Medpace : Q1 2020 Earnings Presentation | MarketScreener  2020/04/28 20:38:10 MarketScreener
Q1 2020 FINANCIAL RESULTS APRIL 28, 2020 F O RWA R D L O O K I N G S TAT E M E N T S & … | April 28, 2020
   Medpace Holdings, Inc. Reports First Quarter 2020 Results  2020/04/28 20:15:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2020. First Quarter 2020 Financial Results Revenue for the three months ended March 31, 2020 increased 15.0% to $230.9 million, compared to $200.7 million for the comparable prior-year period. On a constant currency organic basis, revenue for the first quarter of 2020 increased 15.2% compared to the first quarter of 2019. Backlog as of March 31,
   Medpace Holdings, Inc. to Report First Quarter 2020 Financial Results on April 28, 2020  2020/04/03 20:05:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq:MEDP) (“Medpace”) today announced that it will report its first quarter 2020 financial results after the market close on Tuesday, April 28, 2020. The Company will host a conference call the following morning, Wednesday, April 29, 2020, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 5203559. To access the conference call via

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 メッドペ―ス・ホ―ルディングス MEDP Medpace Holdings Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)